Active ingredients, excipients and the global raw-material supply chain behind Pakistan’s medicines.
India’s bulk-drug incentive scheme has attracted Rs5,210 crore and is commissioning plants for penicillin G, clavulanic acid and paracetamol’s raw material.
Cost, scale and concentration make China central to generic APIs. Tariffs, rebates and quality enforcement are changing the picture.
Biocatalysis and greener solvents cut steps and waste. The world’s leading drug makers are investing — and the tools are openly shared.
New excipients can enable abuse-deterrent and better-absorbed medicines. Why regulators created a special review route, and what it means for…
China is the largest international presence in the 2026 exhibitor list. Why that matters for an industry that imports most of its raw materials.
Pakistan makes most of its finished medicines but imports nearly all its active ingredients, mostly from China. The case for localisation, and what…
